Matches in Wikidata for { <http://www.wikidata.org/entity/Q61980029> ?p ?o ?g. }
Showing items 1 to 61 of
61
with 100 items per page.
- Q61980029 description "clinical trial" @default.
- Q61980029 description "ensayo clínico" @default.
- Q61980029 description "ensayu clínicu" @default.
- Q61980029 description "klinisch onderzoek" @default.
- Q61980029 description "клінічне випробування" @default.
- Q61980029 description "կլինիկական փորձարկում" @default.
- Q61980029 description "临床试验" @default.
- Q61980029 name "Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration" @default.
- Q61980029 type Item @default.
- Q61980029 label "Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration" @default.
- Q61980029 prefLabel "Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration" @default.
- Q61980029 P1050 Q61980029-DE63261F-C7BE-4D2C-8ECB-540805D6F871 @default.
- Q61980029 P1132 Q61980029-8F5B4788-3029-4C25-9926-4F4AC74B3D6D @default.
- Q61980029 P1476 Q61980029-7CBCB5BD-AB20-4769-A8A9-8D82B8BEE5FA @default.
- Q61980029 P17 Q61980029-1400B7F4-3BDC-4D0F-94DA-B70618A538FB @default.
- Q61980029 P17 Q61980029-18F26F9D-EBC2-431A-ABF3-9875BC5DCFDB @default.
- Q61980029 P17 Q61980029-1F2E6D41-72BE-4985-83BF-9346DF2DEBE7 @default.
- Q61980029 P17 Q61980029-535EE5B5-D02D-42EE-A069-29F2F4FD4DDE @default.
- Q61980029 P17 Q61980029-77988CE3-7CE2-48DE-BA67-C125B01A209D @default.
- Q61980029 P17 Q61980029-966C2932-9271-4DE4-8C0A-767D9C1A4F2D @default.
- Q61980029 P17 Q61980029-96A497F1-FAEC-433E-A99D-5FDFCB6A55C7 @default.
- Q61980029 P17 Q61980029-D6233ECA-A841-4B48-96A1-B81D2265A079 @default.
- Q61980029 P17 Q61980029-EC1812E7-3F9C-4DEB-B7BE-82D35752148C @default.
- Q61980029 P17 Q61980029-FCBC5413-140D-47ED-8F01-D0060FD8C766 @default.
- Q61980029 P2899 Q61980029-37BCA604-C3D3-478C-A25F-51F4B86ABADF @default.
- Q61980029 P3098 Q61980029-F8C846C8-24A0-4309-A89F-41CB75E5DE01 @default.
- Q61980029 P31 Q61980029-21690C0E-D9EF-4BDA-B4C1-40D4AA3F260E @default.
- Q61980029 P4844 Q61980029-73F43C8A-5BAB-458C-8890-883B6EE181E8 @default.
- Q61980029 P580 Q61980029-18F33AA7-2C3A-4A6A-8B4C-DDC3F794FAE1 @default.
- Q61980029 P582 Q61980029-F46FA664-B39A-4AEC-8C02-2CE130F1E63D @default.
- Q61980029 P6099 Q61980029-F277DAAF-DC71-4DEA-9013-86116F35602E @default.
- Q61980029 P6153 Q61980029-C6147C86-48DC-49CF-AAC9-141B4D1895F0 @default.
- Q61980029 P8005 Q61980029-5AD719DF-8B07-4EF7-B5C2-4280737E9820 @default.
- Q61980029 P8363 Q61980029-C39347AD-E8DE-4E25-8944-3818C7FC5DB0 @default.
- Q61980029 P859 Q61980029-B972B7EE-983A-4E52-8C20-0D043802209B @default.
- Q61980029 P921 Q61980029-969A342F-C81A-45AE-8EB3-C625A75D15F9 @default.
- Q61980029 P1050 Q27429789 @default.
- Q61980029 P1132 "+234" @default.
- Q61980029 P1476 "A Phase IV, Long-term, Open-label, Multicenter Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)" @default.
- Q61980029 P17 Q145 @default.
- Q61980029 P17 Q183 @default.
- Q61980029 P17 Q28 @default.
- Q61980029 P17 Q29 @default.
- Q61980029 P17 Q31 @default.
- Q61980029 P17 Q408 @default.
- Q61980029 P17 Q43 @default.
- Q61980029 P17 Q45 @default.
- Q61980029 P17 Q55 @default.
- Q61980029 P17 Q801 @default.
- Q61980029 P2899 "+50" @default.
- Q61980029 P3098 "NCT00504959" @default.
- Q61980029 P31 Q30612 @default.
- Q61980029 P4844 Q414270 @default.
- Q61980029 P580 "2007-07-01T00:00:00Z" @default.
- Q61980029 P582 "2010-01-01T00:00:00Z" @default.
- Q61980029 P6099 Q42825046 @default.
- Q61980029 P6153 Q507154 @default.
- Q61980029 P8005 Q76651189 @default.
- Q61980029 P8363 Q78089383 @default.
- Q61980029 P859 Q507154 @default.
- Q61980029 P921 Q7916454 @default.